Whether D4A, a pan inhibitor of androgen biosynthetic enzymes, sensitised CRPC with high HSD3B1 expression (e.g., SPRY2‐deficient CRPC tumours) to ADT requires further investigation. Here, SPRY2 is linked to neoplasm.